Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial

Barts Health NHS Trust, University College London, Queen Mary University of London, The Royal Free Hospital, Fox Chase Cancer Center, Centre Hospitalier de l’Université de Montréal, The Christie NHS Foundation Trust, Ministry of Health, Dnipropetrovsk State Medical Academy, Federal State Budgetary Institution Russian Scientific Center of Roentgenoradiology, Central Clinical Hospital and Polyclinic, Université Laval, Palacký University Olomouc, Sumy State University, Hospital de Clínicas de Porto Alegre, Centre Antoine Lacassagne, Université Côte d'Azur, Tallaght University Hospital, University College Dublin, University of Tübingen, Osaka City University Hospital, Merck & Co., Inc., Rahway, NJ, USA (United States), MSD (UK) Limited (United Kingdom), Georgetown Lombardi Comprehensive Cancer Center, Vanderbilt-Ingram Cancer Center, Cleveland Clinic, Vanderbilt University